$KRYS
Krystal Biotech, Inc. Stock $krys

$krys Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000171127924000056 Filed on November 04, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$83.84M	$8.600M
YoY Change		874.9%
Cost Of Revenue		$6.684M	$220.0K
YoY Change		2938.18%
Gross Profit		$77.16M	$8.330M
YoY Change		826.25%
Gross Profit Margin		92.03%	96.86%
Selling, General & Admin		$28.71M	$23.70M
YoY Change		21.17%	18.87%
% of Gross Profit		37.21%	284.48%
Research & Development		$13.51M	$10.63M
YoY Change		27.11%	-7.7%
% of Gross Profit		17.51%	127.6%
Depreciation & Amortization		$1.300M	$1.200M
YoY Change		8.33%	79.37%
% of Gross Profit		1.68%	14.41%
Operating Expenses		$61.41M	$34.55M
YoY Change		77.74%	9.85%
Operating Profit		$22.43M	-$25.99M
YoY Change		-186.3%	-17.35%
Interest Expense		$7.336M	$6.740M
YoY Change		8.84%
% of Operating Profit		32.7%
Other Income/Expense, Net
YoY Change
Pretax Income		$29.77M	$80.75M
YoY Change		-63.13%	-370.52%
Income Tax		$2.600M	$0.00
% Of Pretax Income		8.73%	0.0%
Net Earnings		$27.18M	$80.75M
YoY Change		-66.34%	-370.51%
Net Earnings / Revenue		32.42%	938.92%
Basic Earnings Per Share		$0.95	$2.88
Diluted Earnings Per Share		$0.91	$2.79
COMMON SHARES
Basic Shares Outstanding	28.76M shares	28.73M shares	27.99M shares
Diluted Shares Outstanding		29.90M shares	28.89M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$588.3M	$562.1M
YoY Change	4.67%	42.51%
Cash & Equivalents	$374.0M	$373.2M
Short-Term Investments	$214.4M	$188.8M
Other Short-Term Assets	$8.961M	$5.500M
YoY Change	62.93%	74.16%
Inventory	$18.58M	$5.278M
Prepaid Expenses
Receivables	$97.30M	$9.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$713.2M	$582.1M
YoY Change	22.51%	46.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$156.6M	$164.0M
YoY Change	-4.53%	3.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$105.9M	$36.50M
YoY Change	190.1%	190.67%
Other Assets	$203.0K	$285.0K
YoY Change	-28.77%	39.02%
Total Long-Term Assets	$269.2M	$208.2M
YoY Change	29.26%	16.45%
TOTAL ASSETS
Total Short-Term Assets	$713.2M	$582.1M
Total Long-Term Assets	$269.2M	$208.2M
Total Assets	$982.3M	$790.4M
YoY Change	24.29%	37.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.580M	$4.340M
YoY Change	28.57%	-24.67%
Accrued Expenses	$80.77M	$20.80M
YoY Change	288.32%	-4.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$89.53M	$27.58M
YoY Change	224.57%	-1.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$761.0K	$6.800M
YoY Change	-88.81%	-10.23%
Total Long-Term Liabilities	$761.0K	$6.800M
YoY Change	-88.81%	-10.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$89.53M	$27.58M
Total Long-Term Liabilities	$761.0K	$6.800M
Total Liabilities	$96.47M	$34.40M
YoY Change	180.43%	-3.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$226.1M	-$278.5M
YoY Change	-18.82%	11.98%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$885.8M	$755.9M
YoY Change
Total Liabilities & Shareholders Equity	$982.3M	$790.4M
YoY Change	24.29%	37.12%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	$27.18M	$80.75M
YoY Change	-66.34%	-370.51%
Depreciation, Depletion And Amortization	$1.300M	$1.200M
YoY Change	8.33%	79.37%
Cash From Operating Activities	$58.86M	-$21.22M
YoY Change	-377.37%	7.78%
INVESTING ACTIVITIES
Capital Expenditures	$1.046M	$1.780M
YoY Change	-41.24%	-112.66%
Acquisitions
YoY Change
Other Investing Activities	-$33.28M	$107.0M
YoY Change	-131.11%	-15670.6%
Cash From Investing Activities	-$34.33M	$105.2M
YoY Change	-132.63%	-813.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.365M	13.39M
YoY Change	-74.87%	531.6%
NET CHANGE
Cash From Operating Activities	58.86M	-21.22M
Cash From Investing Activities	-34.33M	105.2M
Cash From Financing Activities	3.365M	13.39M
Net Change In Cash	27.89M	97.36M
YoY Change	-71.35%	-401.32%
FREE CASH FLOW
Cash From Operating Activities	$58.86M	-$21.22M
Capital Expenditures	$1.046M	$1.780M
Free Cash Flow	$57.81M	-$23.00M
YoY Change	-351.35%	308.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
	dei	Entity Address City Or Town EntityAddressCityOrTown	Pittsburgh
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15203
	dei	City Area Code CityAreaCode	412
	dei	Local Phone Number LocalPhoneNumber	586-5830
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	KRYS
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	346000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1205000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	203000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	263000	usd
CY2024Q3	us-gaap	Assets Assets	982318000	usd
CY2023Q4	us-gaap	Assets Assets	818355000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10023000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-937000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	932000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	799242000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13781000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-335000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	15568000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	838893000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	522231000	usd
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1186000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29902000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	37500000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
	us-gaap	Operating Expenses OperatingExpenses	175060000	usd
	us-gaap	Operating Expenses OperatingExpenses	121421000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25993000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	24316000	usd
CY2024Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	29769000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	80747000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	46746000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2589000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	34549000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	27180000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	209854000	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1080209
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Wharton Street
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28760548	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	373966000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	358328000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	214358000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	173850000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97298000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42040000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	18581000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6985000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8961000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6706000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	713164000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	587909000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156592000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161202000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	105888000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	61954000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6471000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7027000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4132000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1292000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1474000	usd
CY2024Q3	krys	Accrued Rebates Current AccruedRebatesCurrent	29545000	usd
CY2023Q4	krys	Accrued Rebates Current AccruedRebatesCurrent	5977000	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	53110000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	21511000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	89527000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33094000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6184000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6620000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28757000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28757000	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Krystal Biotech, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5580000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	761000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2024Q3	us-gaap	Liabilities Liabilities	96472000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	39714000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28237000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28237000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1110481000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1047830000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1512000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	638000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-226147000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-269827000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	885846000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778641000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83841000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8556000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	982318000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	818355000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	199376000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8556000	usd
CY2024Q3	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	6684000	usd
CY2023Q3	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	223000	usd
	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	15112000	usd
	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	223000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13511000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10629000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40050000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35061000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28713000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23697000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82398000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73637000	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	61408000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-112865000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001711279
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	199376000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8556000	usd
CY2024Q3	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	6684000	usd
CY2023Q3	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	223000	usd
	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	15112000	usd
	krys	Cost Of Goods And Services Sold Operating CostOfGoodsAndServicesSoldOperating	223000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13511000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10629000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40050000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35061000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28713000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23697000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82398000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73637000	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	61408000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	22433000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-112865000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	7336000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6740000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	22430000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	15105000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2240000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3066000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	80747000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2146000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	874000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29326000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	80601000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	44554000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2586000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28716000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28042000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28537000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26812000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29902000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28892000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29669000	shares
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	7336000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6740000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	22430000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	15105000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2240000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3066000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	80747000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2146000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	874000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29326000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	80601000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	44554000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2586000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28716000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28042000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28537000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26812000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29902000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28892000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29669000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27385000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778641000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15969000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-4181000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10637000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3365000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14262000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2146000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	27180000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	885846000	usd
CY2024Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-62000	usd
CY2024Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-83000	usd
CY2024Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	306000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2208000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	749000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10599000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	574000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-45297000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	489566000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	159951000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25446000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11443000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-82000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27385000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778641000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15969000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-4181000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10637000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3365000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14262000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2146000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	27180000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	885846000	usd
CY2024Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-62000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2208000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	749000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10599000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	574000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-45297000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	489566000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	159951000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25446000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11443000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-82000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-33210000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	653114000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13511000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8722000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	80747000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	755948000	usd
CY2023Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-35000	usd
CY2023Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	57000	usd
CY2023Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000	usd
	us-gaap	Depreciation Depreciation	4603000	usd
	us-gaap	Depreciation Depreciation	3483000	usd
	krys	Accretion Expense Net AccretionExpenseNet	-1535000	usd
	krys	Accretion Expense Net AccretionExpenseNet	-1585000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	556000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	671000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35771000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30080000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	4427000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	3886000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	725000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-77000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55257000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9316000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5386000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3983000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2636000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	464000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-11000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	48000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-33210000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	653114000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13511000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8722000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	80747000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	755948000	usd
CY2023Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-35000	usd
CY2023Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	57000	usd
CY2023Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000	usd
	us-gaap	Depreciation Depreciation	4603000	usd
	us-gaap	Depreciation Depreciation	3483000	usd
	krys	Accretion Expense Net AccretionExpenseNet	-1535000	usd
	krys	Accretion Expense Net AccretionExpenseNet	-1585000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	556000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	671000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35771000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30080000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	4427000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	3886000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	725000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-77000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55257000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9316000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5386000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3983000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2636000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	464000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-11000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	48000	usd
	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-617000	usd
	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-603000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	761000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1602000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	121000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2092000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	875000	usd
	krys	Increase Decrease In Accrued Rebates IncreaseDecreaseInAccruedRebates	23568000	usd
	krys	Increase Decrease In Accrued Rebates IncreaseDecreaseInAccruedRebates	920000	usd
	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	31250000	usd
	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	70577000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81572000	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	100000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3437000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9952000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	314268000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	425870000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	238044000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	428620000	usd
	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-617000	usd
	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-603000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	761000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1602000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	121000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2092000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	875000	usd
	krys	Increase Decrease In Accrued Rebates IncreaseDecreaseInAccruedRebates	23568000	usd
	krys	Increase Decrease In Accrued Rebates IncreaseDecreaseInAccruedRebates	920000	usd
	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	31250000	usd
	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	70577000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81572000	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	100000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3437000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9952000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	314268000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	425870000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	238044000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	428620000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-79661000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92798000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	159716000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29972000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41164000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24586000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200131000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15638000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	211341000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	358328000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	161900000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	373241000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8292000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11103000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5150000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q3	krys	Number Of In House Manufacturing Facilities NumberOfInHouseManufacturingFacilities	2	facility
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-226100000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	588300000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-79661000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92798000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	159716000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29972000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41164000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24586000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200131000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15638000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	211341000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	358328000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	161900000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	373966000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	373241000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8292000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11103000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5150000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q3	krys	Number Of In House Manufacturing Facilities NumberOfInHouseManufacturingFacilities	2	facility
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-226100000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	588300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the period these variances become known. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, accrued expenses, the fair value of financial instruments and the valuation allowance included in the deferred income tax calculation.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the period these variances become known. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, accrued expenses, the fair value of financial instruments and the valuation allowance included in the deferred income tax calculation.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></div>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7114000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	37960000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	11621000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33453000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	761000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7114000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	37960000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	11621000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33453000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	761000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28716000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28042000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28537000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26812000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	850000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1132000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	573000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28892000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29669000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27385000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2024Q3	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	692722000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1526000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	36000	usd
CY2024Q3	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	694212000	usd
CY2023Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	593355000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	835000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	58000	usd
CY2023Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	594132000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	27180000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	80747000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43680000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2240000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28042000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28537000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26812000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	850000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1132000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	573000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28892000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29669000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27385000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2024Q3	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	692722000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1526000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	36000	usd
CY2024Q3	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	694212000	usd
CY2023Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	593355000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	835000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	58000	usd
CY2023Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	594132000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8981000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3154000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6390000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3204000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3210000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8981000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3154000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6390000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3204000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3210000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	627000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	18581000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6985000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	176383000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	174029000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19791000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12827000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156592000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161202000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	1300000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1200000	usd
	us-gaap	Depreciation Depreciation	4600000	usd
	us-gaap	Depreciation Depreciation	3500000	usd
CY2024Q3	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	1000000.0	usd
CY2023Q3	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	391000	usd
	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	2400000	usd
	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	464000	usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	31250000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2024Q3	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	6714000	usd
CY2023Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	8778000	usd
CY2024Q3	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	4873000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	627000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	18581000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6985000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	176383000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	174029000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19791000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12827000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156592000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161202000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	1300000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1200000	usd
	us-gaap	Depreciation Depreciation	4600000	usd
	us-gaap	Depreciation Depreciation	3500000	usd
CY2024Q3	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	1000000.0	usd
CY2023Q3	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	391000	usd
	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	2400000	usd
	krys	Depreciation Expense Capitalized DepreciationExpenseCapitalized	464000	usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	31250000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2024Q3	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	6714000	usd
CY2023Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	8778000	usd
CY2024Q3	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	4873000	usd
CY2023Q4	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	5182000	usd
CY2024Q3	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	3091000	usd
CY2023Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1248000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2604000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1876000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2200000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1810000	usd
CY2024Q3	krys	Accrued Inventory AccruedInventory	1805000	usd
CY2023Q4	krys	Accrued Inventory AccruedInventory	334000	usd
CY2024Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	573000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	2283000	usd
CY2024Q3	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	53110000	usd
CY2023Q4	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	5182000	usd
CY2024Q3	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	3091000	usd
CY2023Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1248000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2604000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1876000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2200000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1810000	usd
CY2024Q3	krys	Accrued Inventory AccruedInventory	1805000	usd
CY2023Q4	krys	Accrued Inventory AccruedInventory	334000	usd
CY2024Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	573000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	2283000	usd
CY2024Q3	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	53110000	usd
CY2023Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	21511000	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	37500000	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	31250000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	386000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1277000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1277000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1325000	usd
CY2024Q3	krys	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	9437000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15002000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7526000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	7476000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	260000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	379000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	905000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1282000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	66000	usd
CY2023Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	21511000	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	37500000	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	12500000	usd
CY2024Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	31250000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	386000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1277000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1277000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1325000	usd
CY2024Q3	krys	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	9437000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15002000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7526000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	7476000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	260000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	379000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	905000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1282000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	66000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	62000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	156000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	150000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	326000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	441000	usd
	us-gaap	Lease Cost LeaseCost	1061000	usd
	us-gaap	Lease Cost LeaseCost	1432000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	62000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	156000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	150000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	326000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	441000	usd
	us-gaap	Lease Cost LeaseCost	1061000	usd
	us-gaap	Lease Cost LeaseCost	1432000	usd
	krys	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Period Increase Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent	0.04
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2606592	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	150405000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	297202	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	168.54
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	489152	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	61.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	335449	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	70.52
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2079193	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	81.53
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	867025	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	102627000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3582181	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	61.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	64880000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	419780	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	91.38
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	710734	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	57.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	623967	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	64.19
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2667260	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	133648000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	707277	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	55.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42793000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5900000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13500000	usd
	krys	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Period Increase Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent	0.04
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2606592	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	150405000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	297202	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	168.54
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	489152	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	61.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	335449	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	70.52
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	867025	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	102627000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3582181	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	61.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	64880000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	419780	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	91.38
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	710734	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	57.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	623967	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	64.19
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2667260	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	133648000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	707277	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	55.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42793000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5900000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	50200000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	41400000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	50200000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	41400000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2600000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3100000	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000.0	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2600000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3100000	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	100000000.0	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001711279-24-000056-index-headers.html	Edgar Link	pending
0001711279-24-000056-index.html	Edgar Link	pending
0001711279-24-000056.txt	Edgar Link	pending
0001711279-24-000056-xbrl.zip	Edgar Link	pending
a3q24krysex311.htm	Edgar Link	pending
a3q24krysex312.htm	Edgar Link	pending
a3q24krysex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
krys-20240930.htm	Edgar Link	pending
krys-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
krys-20240930_def.xml	Edgar Link	unprocessable
krys-20240930_lab.xml	Edgar Link	unprocessable
krys-20240930_pre.xml	Edgar Link	unprocessable
krys-20240930_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
krys-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRYS
Krystal Biotech, Inc. Stock $krys

2024 Q4 Form 10-Q Financial Statement

#000171127924000056 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS Krystal Biotech, Inc. Stock $krys

2024 Q4 Form 10-Q Financial Statement

#000171127924000056 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS
Krystal Biotech, Inc. Stock $krys